SU 3327

Key Product Details

Product Description

SU 3327 is a selective inhibitor of c-Jun N-terminal kinase (JNK) (IC₅₀ = 0.7 μM). Inhibits the protein-protein interaction between JNK and JIP (IC₅₀ = 239 nM). Displays selectivity over p38 MAPK and Akt. Restores insulin sensitivity in a mouse model of type-2 diabetes. Displays antibiotic activity against a range of bacteria including S.aureus, A.baumanni, C.difficile and M.tuberculosis.

Product Specifications for SU 3327

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for SU 3327

The following data is based on the product molecular weight 261.30.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	3.83 mL	19.14 mL	38.27 mL
5 mM	0.77 mL	3.83 mL	7.65 mL
10 mM	0.38 mL	1.91 mL	3.83 mL
50 mM	0.08 mL	0.38 mL	0.77 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 14 publications citing the usage of this product.

• Higashihira Halicin is effective against staphylococcus aureus biofilms in vitro. Clin.Orthop.Relat.Res. 2022 PMID: 35583504
• De Design, synthesis and structure-activity relationship of substrate competitive, selective, and in vivo active triazole and thiadiazole inhibitors of the c-jun N-terminal kinase. J.Med.Chem. 2009 PMID: 19271755

Product Documents for SU 3327